Ideaya Biosciences announced initiation of a Phase 2 expansion of the darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDYA:
- Stifel disagrees with negative reaction in Ideaya shares after Amgen data
- Ideaya has positive read from Amgen PRMT5 data, says Oppenheimer
- Ideaya Biosciences selects Werner Helicase Inhibitor Development DC with GSK
- Ideaya Biosciences participates in a conference call with JPMorgan
- Ideaya Biosciences granted IDE161 fast track designation in second indication